Multidisciplinary	O
Care	O
of	O
Patients	O
with	O
Intrahepatic	B-DS
Cholangiocarcinoma	I-DS
:	O
Updates	O
in	O
Management	O

Academic	O
Editor	O
:	O
Massimo	O
Pancione	O

Cholangiocarcinoma	B-DS
is	O
a	O
highly	O
fatal	O
primary	O
cancer	B-DS
of	I-DS
the	I-DS
bile	I-DS
ducts	I-DS
which	O
arises	O
from	O
malignant	O
transformation	O
of	O
bile	O
duct	O
epithelium	O
.	O

While	O
being	O
an	O
uncommon	O
malignancy	O
with	O
an	O
annual	O
incidence	O
in	O
the	O
United	O
States	O
of	O
5000	O
new	O
cases	O
,	O
the	O
incidence	O
has	O
been	O
increasing	O
over	O
the	O
past	O
30	O
years	O
and	O
comprises	O
3	O
%	O
of	O
all	O
gastrointestinal	B-DS
cancers	I-DS
.	O

Cholangiocarcinoma	B-DS
can	O
be	O
classified	O
into	O
intrahepatic	O
(	O
ICC	B-DS
)	O
and	O
extrahepatic	O
(	O
including	O
hilar	O
and	O
distal	O
bile	O
duct	O
)	O
according	O
to	O
its	O
anatomic	O
location	O
within	O
the	O
biliary	O
tree	O
with	O
respect	O
to	O
the	O
liver	O
.	O

This	O
paper	O
reviews	O
the	O
management	O
of	O
ICC	B-DS
,	O
focusing	O
on	O
the	O
epidemiology	O
,	O
risk	O
factors	O
,	O
diagnosis	O
,	O
and	O
surgical	O
and	O
nonsurgical	O
management	O
.	O

1	O
.	O

Introduction	O

Cholangiocarcinoma	B-DS
is	O
a	O
highly	O
fatal	O
primary	O
cancer	B-DS
of	I-DS
the	I-DS
bile	I-DS
ducts	I-DS
that	O
arises	O
from	O
malignant	O
transformation	O
of	O
bile	O
duct	O
epithelium	O
.	O

Recent	O
research	O
in	O
mouse	B-OG
models	O
suggests	O
the	O
possibility	O
that	O
cholangiocarcinoma	B-DS
can	O
arise	O
directly	O
from	O
the	O
transdifferentiation	O
of	O
hepatocytes	O
[	O
1	O
,	O
2	O
].	O

Cholangiocarcinoma	B-DS
can	O
be	O
classified	O
into	O
intrahepatic	O
(	O
ICC	B-DS
)	O
and	O
extrahepatic	O
(	O
including	O
hilar	O
and	O
distal	O
bile	O
duct	O
)	O
according	O
to	O
its	O
anatomic	O
location	O
within	O
the	O
biliary	O
tree	O
with	O
respect	O
to	O
the	O
liver	O
.	O

While	O
being	O
an	O
uncommon	O
malignancy	O
with	O
an	O
annual	O
incidence	O
in	O
the	O
United	O
States	O
of	O
5000	O
new	O
cases	O
,	O
the	O
incidence	O
of	O
ICC	B-DS
has	O
been	O
increasing	O
over	O
the	O
past	O
30	O
years	O
and	O
comprises	O
3	O
%	O
of	O
all	O
gastrointestinal	B-DS
cancers	I-DS
.	O

ICC	B-DS
can	O
arise	O
in	O
patients	O
both	O
with	O
a	O
normal	O
liver	O
and	O
with	O
underlying	O
chronic	B-DS
liver	I-DS
disease	I-DS
[	O
3	O
].	O

2	O
.	O

Epidemiology	O

ICC	B-DS
accounts	O
for	O
10	O
–	O
15	O
%	O
of	O
all	O
primary	B-DS
liver	I-DS
cancers	I-DS
worldwide	O
and	O
is	O
the	O
second	O
most	O
common	O
primary	O
liver	O
malignancy	O
after	O
hepatocellular	B-DS
carcinoma	I-DS
with	O
a	O
varying	O
incidence	O
worldwide	O
.	O

The	O
highest	O
recorded	O
incidence	O
is	O
in	O
Thailand	O
(>	O
80	O
/	O
100	O
,	O
000	O
population	O
)	O
[	O
4	O
]	O
whereas	O
there	O
is	O
a	O
much	O
lower	O
incidence	O
in	O
the	O
Western	O
world	O
(	O
US	O
:	O
1	O
.	O
67	O
/	O
100	O
,	O
000	O
and	O
Canada	O
:	O
0	O
.	O
35	O
/	O
100	O
,	O
000	O
)	O
[	O
3	O
,	O
4	O
].	O

The	O
global	O
incidence	O
of	O
ICC	B-DS
has	O
been	O
increasing	O
[	O
5	O
].	O

For	O
example	O
,	O
the	O
estimated	O
age	O
-	O
adjusted	O
incidence	O
of	O
ICC	B-DS
in	O
the	O
United	O
States	O
increased	O
by	O
165	O
%	O
from	O
1979	O
to	O
1999	O
(	O
from	O
0	O
.	O
32	O
per	O
100	O
,	O
000	O
in	O
1975	O
to	O
1979	O
to	O
0	O
.	O
85	O
per	O
100	O
,	O
000	O
in	O
1995	O
to	O
1999	O
),	O
with	O
a	O
majority	O
of	O
the	O
increase	O
observed	O
after	O
1985	O
[	O
6	O
].	O

An	O
increase	O
in	O
incidence	O
has	O
also	O
been	O
seen	O
in	O
other	O
countries	O
such	O
as	O
the	O
United	O
Kingdom	O
[	O
7	O
]	O
and	O
Japan	O
[	O
8	O
].	O

Some	O
of	O
this	O
increase	O
in	O
incidence	O
may	O
be	O
attributed	O
to	O
the	O
disease	O
being	O
historically	O
underdiagnosed	O
due	O
to	O
less	O
sophisticated	O
radiologic	O
and	O
endoscopic	O
imaging	O
,	O
as	O
well	O
as	O
misclassification	O
.	O

Welzel	O
et	O
al	O
.	O
reported	O
,	O
however	O
,	O
that	O
the	O
increase	O
incidence	O
of	O
ICC	B-DS
was	O
a	O
“	O
real	O
”	O
phenomenon	O
even	O
when	O
taking	O
into	O
account	O
previous	O
misclassification	O
[	O
9	O
].	O

In	O
addition	O
to	O
a	O
rising	O
incidence	O
,	O
an	O
increase	O
in	O
mortality	O
rates	O
from	O
ICC	B-DS
has	O
also	O
been	O
reported	O
in	O
the	O
US	O
,	O
UK	O
,	O
Italy	O
,	O
and	O
Germany	O
.	O

A	O
study	O
in	O
the	O
US	O
found	O
an	O
increase	O
in	O
mortality	O
rates	O
in	O
ICC	B-DS
between	O
1973	O
and	O
1997	O
with	O
an	O
estimated	O
annual	O
percent	O
change	O
of	O
9	O
.	O
4	O
%	O
[	O
10	O
].	O

A	O
different	O
study	O
in	O
the	O
UK	O
reported	O
a	O
15	O
-	O
fold	O
increase	O
in	O
age	O
specific	O
mortality	O
rates	O
(	O
from	O
0	O
.	O
1	O
to	O
1	O
.	O
5	O
/	O
100	O
,	O
000	O
population	O
)	O
between	O
1968	O
and	O
1996	O
[	O
11	O
].	O

Mortality	O
from	O
ICC	B-DS
tripled	O
in	O
Germany	O
between	O
1998	O
and	O
2008	O
[	O
12	O
].	O

Italy	O
noted	O
an	O
even	O
more	O
dramatic	O
increase	O
in	O
mortality	O
rates	O
between1980	O
and	O
2003	O
,	O
reporting	O
an	O
increase	O
from	O
0	O
.	O
2	O
to	O
5	O
.	O
9	O
/	O
million	O
[	O
13	O
].	O

3	O
.	O

Risk	O
Factors	O

There	O
are	O
several	O
risk	O
factors	O
associated	O
with	O
ICC	B-DS
and	O
the	O
development	O
of	O
disease	O
is	O
likely	O
multifactorial	O
.	O

The	O
risk	O
of	O
ICC	B-DS
increases	O
with	O
older	O
age	O
as	O
well	O
as	O
female	O
sex	O
.	O

In	O
addition	O
,	O
several	O
other	O
risk	O
factors	O
include	O
primary	B-DS
sclerosing	I-DS
cholangitis	I-DS
,	O
hepatolithiasis	B-DS
,	O
choledochal	B-DS
cysts	I-DS
,	O
primary	B-DS
biliary	I-DS
cirrhosis	I-DS
,	O
parasitic	B-DS
biliary	I-DS
infection	I-DS
with	O
Clonorchis	B-OG
sinensis	I-OG
or	O
Opisthorchis	B-OG
viverrini	I-OG
,	O
inflammatory	B-DS
bowel	I-DS
disease	I-DS
,	O
and	O
chronic	B-DS
pancreatitis	I-DS
[	O
14	O
],	O
as	O
well	O
as	O
the	O
historical	O
use	O
of	O
the	O
radiologic	O
contrast	O
agent	O
Thorotrast	O
.	O

More	O
recently	O
,	O
several	O
risk	O
factors	O
that	O
have	O
traditionally	O
been	O
considered	O
risk	O
factors	O
for	O
hepatocellular	B-DS
carcinoma	I-DS
(	O
HCC	B-DS
)	O
such	O
as	O
alcoholic	B-DS
liver	I-DS
disease	I-DS
[	O
14	O
],	O
obesity	B-DS
[	O
15	O
],	O
diabetes	B-DS
[	O
14	O
,	O
16	O
],	O
cirrhosis	B-DS
,	O
hepatitis	B-DS
B	I-DS
infection	I-DS
[	O
15	O
,	O
17	O
,	O
18	O
],	O
and	O
tobacco	O
use	O
[	O
14	O
]	O
have	O
been	O
implicated	O
in	O
ICC	B-DS
[	O
15	O
].	O

Studies	O
from	O
Korea	O
,	O
Japan	O
,	O
Italy	O
,	O
US	O
,	O
and	O
Denmark	O
have	O
all	O
reported	O
cirrhosis	B-DS
,	O
without	O
distinction	O
of	O
causation	O
,	O
as	O
a	O
risk	O
factor	O
for	O
ICC	B-DS
[	O
16	O
,	O
19	O
–	O
22	O
].	O

A	O
2012	O
meta	O
-	O
analysis	O
of	O
seven	O
case	O
-	O
control	O
studies	O
with	O
a	O
total	O
study	O
population	O
of	O
399	O
,	O
608	O
reported	O
an	O
overall	O
OR	O
of	O
22	O
.	O
92	O
(	O
95	O
%	O
CI	O
:	O
18	O
.	O
24	O
–	O
28	O
.	O
79	O
)	O
for	O
the	O
association	O
between	O
cirrhosis	B-DS
and	O
ICC	B-DS
[	O
15	O
].	O

Of	O
note	O
,	O
with	O
regard	O
to	O
the	O
noted	O
risk	O
factors	O
,	O
there	O
has	O
been	O
no	O
appreciable	O
increase	O
in	O
any	O
specific	O
factor	O
that	O
can	O
fully	O
account	O
for	O
the	O
increase	O
in	O
incidence	O
of	O
ICC	B-DS
over	O
the	O
past	O
30	O
years	O
(	O
Table	O
1	O
).	O

Two	O
risk	O
factors	O
that	O
have	O
increased	O
in	O
incidence	O
worldwide	O
are	O
nonalcoholic	B-DS
fatty	I-DS
liver	I-DS
disease	I-DS
(	O
NAFLD	B-DS
)	O
and	O
hepatitis	B-DS
C	I-DS
.	O

The	O
association	O
between	O
ICC	B-DS
and	O
hepatitis	B-DS
C	I-DS
has	O
been	O
demonstrated	O
in	O
the	O
United	O
States	O
in	O
a	O
study	O
by	O
Shaib	O
et	O
al	O
.	O
that	O
noted	O
that	O
hepatitis	B-DS
C	I-DS
virus	I-DS
infection	I-DS
was	O
significantly	O
more	O
prevalent	O
among	O
ICC	B-DS
cases	O
than	O
controls	O
(	O
adjusted	O
odds	O
ratio	O
:	O
6	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
[	O
16	O
].	O

El	O
-	O
Serag	O
et	O
al	O
.	O
similarly	O
reported	O
an	O
increased	O
risk	O
for	O
ICC	B-DS
in	O
the	O
setting	O
of	O
HCV	B-DS
infection	I-DS
(	O
hazard	O
ratio	O
(	O
HR	O
):	O
2	O
.	O
55	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
):	O
1	O
.	O
31	O
,	O
4	O
.	O
95	O
)	O
[	O
23	O
].	O

The	O
association	O
between	O
HCV	B-OG
and	O
ICC	B-DS
is	O
not	O
unique	O
to	O
the	O
US	O
.	O

In	O
Italy	O
the	O
adjusted	O
increased	O
odds	O
ratio	O
for	O
ICC	B-DS
in	O
the	O
setting	O
of	O
HCV	B-OG
was	O
9	O
.	O
7	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
CI	O
):	O
1	O
.	O
6	O
–	O
58	O
.	O
9	O
)	O
[	O
24	O
],	O
while	O
in	O
Japan	O
cumulative	O
rates	O
of	O
newly	O
diagnosed	O
ICC	B-DS
among	O
HCV	B-OG
patients	O
were	O
1	O
.	O
6	O
%	O
at	O
5	O
years	O
and	O
3	O
.	O
5	O
%	O
at	O
10	O
years	O
,	O
which	O
was	O
1000	O
times	O
higher	O
than	O
the	O
estimated	O
incidence	O
in	O
the	O
general	O
Japanese	O
population	O
[	O
25	O
].	O

NAFLD	B-DS
,	O
which	O
is	O
associated	O
with	O
obesity	B-DS
and	O
metabolic	B-DS
syndrome	I-DS
,	O
is	O
an	O
increasing	O
concern	O
worldwide	O
and	O
especially	O
in	O
the	O
United	O
States	O
.	O

NAFLD	B-DS
can	O
lead	O
to	O
nonalcoholic	B-DS
steatohepatitis	I-DS
(	O
NASH	B-DS
),	O
eventual	O
cirrhosis	B-DS
,	O
and	O
HCC	B-DS
[	O
26	O
].	O

Recently	O
,	O
investigators	O
have	O
looked	O
at	O
these	O
factors	O
in	O
the	O
setting	O
of	O
cholangiocarcinoma	B-DS
.	O

Metabolic	B-DS
syndrome	I-DS
was	O
implicated	O
as	O
a	O
risk	O
factor	O
for	O
ICC	B-DS
(	O
odds	O
ratio	O
:	O
1	O
.	O
56	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
32	O
–	O
1	O
.	O
83	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
by	O
Welzel	O
et	O
al	O
.	O
who	O
evaluated	O
743	O
ICC	B-DS
cases	O
from	O
the	O
SEER	O
database	O
diagnosed	O
between	O
1993	O
and	O
2005	O
[	O
14	O
].	O

In	O
a	O
separate	O
study	O
from	O
the	O
UK	O
,	O
the	O
authors	O
reported	O
that	O
a	O
BMI	O
>	O
30	O
kg	O
/	O
m2	O
was	O
associated	O
with	O
a	O
1	O
.	O
5	O
increased	O
risk	O
of	O
cholangiocarcinoma	B-DS
compared	O
with	O
patients	O
who	O
had	O
a	O
BMI	O
<	O
25	O
kg	O
/	O
m2	O
(	O
OR	O
:	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
03	O
–	O
2	O
.	O
24	O
)	O
[	O
27	O
].	O

This	O
study	O
did	O
not	O
,	O
however	O
,	O
stratify	O
patients	O
by	O
type	O
of	O
cholangiocarcinoma	B-DS
.	O

In	O
a	O
different	O
study	O
,	O
Reddy	O
et	O
al	O
.	O
reported	O
that	O
17	O
.	O
1	O
%	O
of	O
patients	O
who	O
underwent	O
resection	O
for	O
ICC	B-DS
at	O
one	O
of	O
8	O
major	O
US	O
hepatobiliary	O
centers	O
had	O
underlying	O
NASH	B-DS
on	O
histology	O
[	O
28	O
].	O

A	O
meta	O
-	O
analysis	O
that	O
combined	O
3	O
case	O
-	O
control	O
studies	O
evaluating	O
obesity	B-DS
as	O
a	O
risk	O
factor	O
for	O
ICC	B-DS
found	O
an	O
overall	O
OR	O
of	O
1	O
.	O
6	O
[	O
15	O
].	O

While	O
many	O
of	O
these	O
risk	O
factors	O
are	O
relatively	O
common	O
,	O
only	O
a	O
very	O
small	O
percentage	O
of	O
patients	O
with	O
ICC	B-DS
actually	O
have	O
an	O
identifiable	O
risk	O
factor	O
.	O

A	O
single	O
institution	O
study	O
of	O
73	O
surgical	O
ICC	B-DS
cases	O
found	O
that	O
48	O
(	O
66	O
%)	O
of	O
these	O
cases	O
had	O
none	O
of	O
the	O
major	O
risk	O
factors	O
including	O
HBV	B-OG
,	O
HCV	B-OG
,	O
PSC	B-DS
,	O
NASH	B-DS
,	O
or	O
alcohol	B-DS
induced	I-DS
cirrhosis	I-DS
[	O
29	O
].	O

As	O
such	O
,	O
it	O
is	O
likely	O
that	O
there	O
are	O
additional	O
contributing	O
factors	O
to	O
the	O
development	O
of	O
ICC	B-DS
.	O

4	O
.	O

Presentation	O

While	O
cholangiocarcinoma	B-DS
of	O
the	O
hilum	O
or	O
distal	O
ducts	O
often	O
presents	O
with	O
biliary	B-DS
obstruction	I-DS
,	O
ICC	B-DS
is	O
often	O
an	O
incidental	O
radiologic	O
finding	O
.	O

Thus	O
,	O
clinical	O
presentation	O
alone	O
is	O
rarely	O
sufficient	O
for	O
diagnosis	O
.	O

At	O
very	O
late	O
stages	O
,	O
patients	O
may	O
develop	O
hepatomegaly	O
,	O
malaise	O
,	O
weight	O
loss	O
,	O
failure	B-DS
to	I-DS
thrive	I-DS
,	O
abdominal	O
pain	O
,	O
night	O
sweats	O
,	O
or	O
jaundice	O
;	O
however	O
,	O
the	O
frequent	O
biliary	B-DS
obstruction	I-DS
seen	O
in	O
hilar	O
or	O
distal	O
lesions	O
is	O
rarely	O
present	O
in	O
ICC	B-DS
.	O

Lesions	O
detected	O
on	O
radiologic	O
imaging	O
can	O
be	O
evaluated	O
using	O
bile	O
duct	O
brushings	O
or	O
biopsied	O
using	O
endoscopic	O
ultrasound	O
and	O
fine	O
needle	O
aspiration	O
(	O
EUS	O
-	O
FNA	O
)	O
to	O
distinguish	O
cholangiocarcinomas	B-DS
from	O
hepatocellular	B-DS
carcinoma	I-DS
and	O
metastatic	B-DS
disease	I-DS
.	O

While	O
there	O
is	O
a	O
theoretical	O
risk	O
of	O
seeding	O
the	O
needle	O
track	O
while	O
performing	O
the	O
biopsy	O
,	O
a	O
2013	O
study	O
by	O
El	O
-	O
Chafic	O
et	O
al	O
.	O
showed	O
that	O
number	O
of	O
needle	O
passes	O
did	O
not	O
have	O
a	O
statistically	O
significant	O
impact	O
on	O
overall	O
survival	O
or	O
progression	O
-	O
free	O
survival	O
[	O
30	O
].	O

Many	O
times	O
,	O
these	O
FNA	O
specimens	O
have	O
subsequent	O
pathology	O
revealing	O
“	O
adenocarcinoma	B-DS
.”	O
Due	O
to	O
the	O
fact	O
that	O
most	O
adenocarcinomas	B-DS
of	O
the	O
liver	O
are	O
metastatic	O
in	O
origin	O
,	O
careful	O
pathologic	O
review	O
and	O
immunohistochemistry	O
staining	O
should	O
be	O
attempted	O
to	O
elucidate	O
the	O
origin	O
of	O
the	O
tumor	B-DS
.	O

Some	O
immunohistochemical	O
markers	O
,	O
including	O
CK7	B-GP
,	O
CK20	B-GP
,	O
CDX	B-GP
-	I-GP
2	I-GP
,	O
TTF	B-GP
-	I-GP
1	I-GP
,	O
ER	B-GP
,	O
PR	B-GP
,	O
BRST	B-GP
-	I-GP
2	I-GP
,	O
AFP	B-GP
,	O
CEA	B-GP
,	O
CA19	O
-	O
9	O
,	O
and	O
PSA	B-GP
,	O
may	O
help	O
to	O
exclude	O
common	O
primary	O
sites	O
including	O
colon	O
,	O
lung	O
,	O
breast	O
,	O
and	O
prostate	O
[	O
29	O
].	O

ICCs	B-DS
are	O
often	O
positive	O
for	O
CK7	B-GP
,	O
CEA	B-GP
,	O
and	O
CA19	O
-	O
9	O
and	O
negative	O
for	O
the	O
other	O
markers	O
listed	O
above	O
.	O

On	O
histology	O
,	O
ICC	B-DS
can	O
show	O
tubular	O
and	O
/	O
or	O
papillary	O
structures	O
often	O
with	O
a	O
fibrous	O
stroma	O
[	O
31	O
–	O
35	O
].	O

This	O
histologic	O
appearance	O
when	O
diagnosed	O
on	O
a	O
core	O
biopsy	O
of	O
the	O
liver	O
can	O
be	O
very	O
similar	O
to	O
the	O
appearance	O
of	O
metastatic	O
lesions	O
to	O
the	O
liver	O
from	O
extrahepatic	B-DS
adenocarcinomas	I-DS
of	O
the	O
foregut	O
[	O
36	O
].	O

A	O
search	O
to	O
rule	O
out	O
an	O
extrahepatic	B-DS
primary	I-DS
tumor	I-DS
should	O
therefore	O
usually	O
be	O
performed	O
using	O
upper	O
and	O
lower	O
endoscopy	O
to	O
rule	O
out	O
occult	O
gastrointestinal	O
malignancy	O
;	O
in	O
addition	O
,	O
cross	O
-	O
sectional	O
imaging	O
of	O
the	O
chest	O
,	O
abdomen	O
,	O
and	O
pelvis	O
to	O
rule	O
out	O
an	O
intrathoracic	O
or	O
intra	O
-	O
abdominal	O
primary	B-DS
tumor	I-DS
can	O
also	O
be	O
helpful	O
.	O

In	O
addition	O
to	O
these	O
imaging	O
studies	O
,	O
laboratory	O
values	O
including	O
tumor	B-DS
markers	O
should	O
be	O
assessed	O
(	O
Figure	O
1	O
).	O

Carcinoembryonic	B-GP
antigen	I-GP
(	O
CEA	B-GP
),	O
alpha	B-GP
-	I-GP
fetoprotein	I-GP
(	O
AFP	B-GP
),	O
and	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
(	O
CA19	O
-	O
9	O
)	O
should	O
be	O
obtained	O
.	O

While	O
the	O
prognostic	O
value	O
of	O
these	O
tumor	B-DS
markers	O
is	O
not	O
well	O
defined	O
,	O
a	O
small	O
report	O
from	O
the	O
Mayo	O
Clinic	O
evaluating	O
50	O
patients	O
found	O
that	O
serum	O
CA19	O
-	O
9	O
>	O
100	O
U	O
/	O
mL	O
was	O
associated	O
with	O
a	O
sensitivity	O
of	O
53	O
%	O
for	O
the	O
diagnosis	O
of	O
cholangiocarcinoma	B-DS
and	O
a	O
specificity	O
of	O
75	O
–	O
90	O
%	O
[	O
37	O
].	O

In	O
a	O
separate	O
study	O
of	O
74	O
patients	O
undergoing	O
surgical	O
resection	O
for	O
ICC	B-DS
,	O
the	O
authors	O
reported	O
that	O
CA	O
19	O
-	O
9	O
levels	O
greater	O
than	O
100	O
U	O
/	O
mL	O
were	O
independently	O
associated	O
with	O
early	O
recurrence	O
and	O
shorter	O
survival	O
after	O
surgical	O
resection	O
[	O
38	O
].	O

However	O
,	O
it	O
must	O
be	O
noted	O
that	O
biliary	B-DS
obstruction	I-DS
and	O
acute	B-DS
cholangitis	I-DS
may	O
also	O
cause	O
an	O
increase	O
in	O
CA19	O
-	O
9	O
;	O
therefore	O
markers	O
should	O
be	O
measured	O
after	O
biliary	O
decompression	O
and	O
drainage	O
.	O

Reports	O
of	O
more	O
specific	O
serum	O
marks	O
such	O
as	O
CYFRA21	B-GP
-	I-GP
1	I-GP
,	O
claudin	B-GP
-	I-GP
4	I-GP
,	O
insulin	B-GP
-	I-GP
like	I-GP
growth	I-GP
factor	I-GP
binding	I-GP
protein	I-GP
5	I-GP
(	O
IGFBP	B-GP
-	I-GP
5	I-GP
),	O
and	O
biglycan	B-GP
exist	O
;	O
however	O
,	O
none	O
of	O
these	O
are	O
routinely	O
clinically	O
used	O
[	O
39	O
,	O
40	O
].	O

4	O
.	O
1	O
.	O

ICC	B-DS
on	O
Cross	O
-	O
Sectional	O
Imaging	O

ICC	B-DS
is	O
often	O
diagnosed	O
as	O
an	O
incidental	O
radiologic	O
finding	O
on	O
cross	O
-	O
sectional	O
imaging	O
performed	O
for	O
other	O
reasons	O
.	O

The	O
radiographic	O
features	O
of	O
classic	O
mass	O
-	O
forming	O
ICC	B-DS
on	O
CT	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
are	O
well	O
described	O
.	O

ICC	B-DS
,	O
however	O
,	O
can	O
often	O
be	O
difficult	O
to	O
diagnose	O
on	O
the	O
basis	O
of	O
radiologic	O
findings	O
alone	O
.	O

On	O
MRI	O
,	O
ICC	B-DS
lesions	O
are	O
generally	O
hypointense	O
on	O
T1	O
-	O
weighted	O
images	O
and	O
heterogeneously	O
hyperintense	O
on	O
T2	O
-	O
weighted	O
images	O
with	O
central	O
hypointensity	O
,	O
indicating	O
central	O
tumor	B-DS
fibrosis	O
[	O
41	O
].	O

Lesions	O
can	O
demonstrate	O
initial	O
rim	O
enhancement	O
characterized	O
by	O
progressive	O
and	O
concentric	O
enhancement	O
and	O
pooling	O
of	O
contrast	O
on	O
dynamic	O
contrast	O
-	O
enhanced	O
MRI	O
that	O
again	O
may	O
indicate	O
fibrosis	O
(	O
Figure	O
2	O
)	O
[	O
41	O
,	O
42	O
].	O

The	O
appearance	O
of	O
ICC	B-DS
on	O
unenhanced	O
CT	O
scan	O
is	O
often	O
as	O
a	O
hypodense	O
mass	O
with	O
irregular	O
margins	O
[	O
43	O
].	O

On	O
contrast	O
-	O
enhanced	O
helical	O
CT	O
,	O
rim	O
-	O
like	O
enhancement	O
at	O
the	O
tumor	B-DS
periphery	O
is	O
usually	O
seen	O
in	O
both	O
the	O
arterial	O
and	O
portal	O
venous	O
phase	O
with	O
gradual	O
centripetal	O
enhancement	O
on	O
delayed	O
imaging	O
[	O
41	O
,	O
44	O
].	O

ICC	B-DS
may	O
only	O
enhance	O
completely	O
on	O
delayed	O
imaging	O
obtained	O
after	O
contrast	O
administration	O
,	O
a	O
finding	O
related	O
to	O
the	O
desmoplastic	O
nature	O
of	O
the	O
tumor	B-DS
.	O

In	O
one	O
study	O
,	O
delayed	O
contrast	O
-	O
enhanced	O
CT	O
performed	O
in	O
47	O
patients	O
with	O
ICC	B-DS
performed	O
6	O
–	O
36	O
minutes	O
after	O
contrast	O
administration	O
showed	O
that	O
74	O
%	O
of	O
tumors	B-DS
had	O
hyperattenuating	O
delayed	O
contrast	O
enhancement	O
[	O
41	O
,	O
45	O
].	O

While	O
imaging	O
may	O
be	O
helpful	O
,	O
it	O
cannot	O
reliably	O
distinguish	O
between	O
ICC	B-DS
,	O
metastatic	B-DS
adenocarcinoma	I-DS
from	O
extrahepatic	O
primaries	O
or	O
HCC	B-DS
with	O
cirrhosis	B-DS
[	O
46	O
].	O

5	O
.	O

Staging	O

Until	O
the	O
most	O
recent	O
7th	O
edition	O
of	O
the	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O
AJCC	O
)/	O
International	O
Union	O
Against	O
Cancer	O
(	O
UICC	O
)	O
guidelines	O
that	O
were	O
published	O
in	O
2010	O
,	O
ICC	B-DS
was	O
staged	O
using	O
criteria	O
for	O
HCC	B-DS
.	O

In	O
fact	O
,	O
prior	O
to	O
the	O
7th	O
edition	O
of	O
AJCC	O
/	O
UICC	O
staging	O
manual	O
,	O
there	O
was	O
no	O
internationally	O
recognized	O
distinct	O
staging	O
system	O
for	O
cholangiocarcinoma	B-DS
[	O
47	O
].	O

Two	O
separate	O
staging	O
systems	O
had	O
,	O
however	O
,	O
been	O
proposed	O
based	O
on	O
data	O
from	O
Japan	O
.	O

The	O
first	O
,	O
proposed	O
by	O
Okabayashi	O
et	O
al	O
.,	O
was	O
based	O
on	O
the	O
multivariate	O
modeling	O
that	O
found	O
the	O
presence	O
of	O
vascular	O
invasion	O
,	O
multiple	B-DS
tumors	I-DS
,	O
symptomatic	O
disease	O
,	O
and	O
regional	B-DS
lymph	I-DS
node	I-DS
metastasis	I-DS
all	O
to	O
be	O
associated	O
with	O
a	O
worse	O
prognosis	O
[	O
48	O
].	O

Taking	O
these	O
four	O
prognostic	O
factors	O
into	O
account	O
,	O
Okaybayashi	O
et	O
al	O
.	O
proposed	O
a	O
staging	O
system	O
irrespective	O
of	O
tumor	B-DS
size	O
:	O
Stage	O
I	O
:	O
solitary	B-DS
tumor	I-DS
without	O
vascular	O
invasion	O
;	O
Stage	O
II	O
:	O
solitary	B-DS
tumor	I-DS
with	O
the	O
presence	O
of	O
vascular	O
invasion	O
;	O
Stage	O
IIIa	O
:	O
multiple	B-DS
tumors	I-DS
with	O
or	O
without	O
the	O
presence	O
of	O
invasion	O
;	O
Stage	O
IIIb	O
:	O
any	O
tumor	B-DS
with	O
involvement	O
of	O
regional	O
lymph	O
nodes	O
;	O
Stage	O
IV	O
:	O
distant	O
metastases	O
[	O
48	O
].	O

A	O
second	O
staging	O
system	O
,	O
proposed	O
by	O
Yamasaki	O
,	O
used	O
a	O
point	O
system	O
to	O
stratify	O
patients	O
based	O
on	O
size	O
(	O
greater	O
than	O
2	O
cm	O
),	O
solitary	O
versus	O
multiple	B-DS
tumors	I-DS
,	O
the	O
presence	O
or	O
absence	O
of	O
peritoneal	O
,	O
portal	O
vein	O
,	O
or	O
hepatic	O
vein	O
invasion	O
[	O
49	O
].	O

Regional	B-DS
lymph	I-DS
node	I-DS
metastasis	I-DS
and	O
distant	O
metastasis	O
were	O
also	O
independently	O
associated	O
with	O
outcome	O
and	O
were	O
therefore	O
included	O
.	O

More	O
recently	O
,	O
Nathan	O
et	O
al	O
.	O
evaluated	O
598	O
patients	O
who	O
underwent	O
surgery	O
for	O
ICC	B-DS
between	O
1988	O
and	O
2004	O
from	O
the	O
SEER	O
database	O
and	O
proposed	O
a	O
new	O
simplified	O
staging	O
system	O
from	O
independent	O
predictors	O
of	O
survival	O
that	O
eventually	O
was	O
largely	O
adopted	O
in	O
the	O
7th	O
edition	O
of	O
the	O
AJCC	O
/	O
UICC	O
staging	O
manual	O
[	O
50	O
].	O

These	O
authors	O
compared	O
the	O
discriminative	O
abilities	O
of	O
the	O
6th	O
edition	O
of	O
AJCC	O
/	O
UICC	O
staging	O
manual	O
as	O
well	O
as	O
the	O
two	O
previously	O
discussed	O
Japanese	O
studies	O
to	O
the	O
newly	O
proposed	O
staging	O
system	O
.	O

The	O
authors	O
noted	O
that	O
the	O
new	O
system	O
had	O
superior	O
discriminatory	O
power	O
.	O

In	O
this	O
analysis	O
,	O
the	O
presence	O
of	O
multiple	B-DS
tumors	I-DS
(	O
HR	O
:	O
1	O
.	O
42	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
01	O
–	O
2	O
.	O
01	O
)	O
and	O
the	O
presence	O
of	O
vascular	O
invasion	O
(	O
HR	O
:	O
1	O
.	O
53	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
10	O
–	O
2	O
.	O
12	O
)	O
were	O
independent	O
predictors	O
of	O
worse	O
prognosis	O
on	O
multivariate	O
analysis	O
[	O
50	O
].	O

Tumor	B-DS
size	O
was	O
not	O
predictive	O
of	O
survival	O
after	O
surgical	O
resection	O
.	O

As	O
such	O
,	O
the	O
staging	O
system	O
proposed	O
by	O
Nathan	O
et	O
al	O
.	O
included	O
3	O
T	O
stages	O
:	O
T1	O
:	O
solitary	B-DS
tumor	I-DS
of	O
any	O
size	O
without	O
vascular	O
invasion	O
,	O
T2	O
:	O
multiple	B-DS
tumors	I-DS
or	O
any	O
tumor	B-DS
with	O
vascular	O
invasion	O
,	O
and	O
T3	O
:	O
extrahepatic	O
extension	O
[	O
50	O
].	O

With	O
the	O
publication	O
of	O
the	O
7th	O
edition	O
of	O
the	O
AJCC	O
/	O
UICC	O
staging	O
manual	O
in	O
2010	O
,	O
ICC	B-DS
is	O
now	O
staged	O
using	O
its	O
own	O
distinct	O
criteria	O
and	O
no	O
longer	O
under	O
the	O
same	O
tumor	B-DS
-	O
node	O
-	O
metastasis	O
(	O
TNM	O
)	O
stages	O
of	O
HCC	B-DS
[	O
47	O
].	O

In	O
the	O
current	O
staging	O
system	O
,	O
tumor	B-DS
size	O
was	O
removed	O
as	O
a	O
prognostic	O
factor	O
.	O

In	O
this	O
system	O
,	O
“	O
T	O
”	O
classification	O
is	O
based	O
on	O
the	O
number	O
of	O
tumors	B-DS
,	O
vascular	O
invasion	O
,	O
and	O
direct	O
invasion	O
of	O
adjacent	O
structures	O
[	O
47	O
].	O

The	O
T	O
classification	O
is	O
defined	O
as	O
follows	O
:	O
T1	O
:	O
solitary	B-DS
tumors	I-DS
without	O
vascular	O
invasion	O
,	O
T2	O
:	O
multiple	B-DS
tumors	I-DS
(	O
multifocal	O
disease	O
,	O
intrahepatic	O
metastasis	O
,	O
or	O
satellite	O
lesions	O
)	O
and	O
any	O
tumor	B-DS
with	O
vascular	O
invasion	O
,	O
T3	O
:	O
any	O
tumor	B-DS
with	O
direct	O
invasion	O
of	O
adjacent	O
organs	O
,	O
and	O
T4	O
:	O
tumors	B-DS
with	O
any	O
periductal	O
-	O
infiltrating	O
component	O
on	O
histology	O
.	O

The	O
“	O
N	O
”	O
and	O
“	O
M	O
”	O
classifications	O
,	O
similar	O
to	O
other	O
solid	O
abdominal	B-DS
tumors	I-DS
,	O
are	O
included	O
with	O
N1	O
disease	O
considered	O
in	O
any	O
patient	O
with	O
hilar	O
,	O
periduodenal	O
,	O
or	O
peripancreatic	O
regional	B-DS
lymph	I-DS
node	I-DS
metastasis	I-DS
and	O
distant	O
metastasis	O
classified	O
as	O
M1	O
disease	O
[	O
47	O
]	O
(	O
Table	O
2	O
).	O

In	O
2011	O
,	O
the	O
7th	O
edition	O
of	O
the	O
AJCC	O
/	O
UICC	O
staging	O
system	O
for	O
ICC	B-DS
was	O
independently	O
validated	O
in	O
France	O
.	O

The	O
authors	O
noted	O
that	O
the	O
7th	O
edition	O
of	O
AJCC	O
/	O
UICC	O
was	O
more	O
discriminating	O
in	O
predicting	O
survival	O
compared	O
with	O
the	O
two	O
Japanese	O
classifications	O
or	O
the	O
5th	O
and	O
6th	O
editions	O
of	O
the	O
AJCC	O
/	O
UICC	O
staging	O
manual	O
[	O
51	O
].	O

There	O
will	O
undoubtedly	O
be	O
more	O
changes	O
to	O
the	O
ICC	B-DS
system	O
in	O
the	O
upcoming	O
8th	O
edition	O
of	O
the	O
AJCC	O
/	O
UICC	O
staging	O
manual	O
as	O
more	O
studies	O
more	O
rigorously	O
evaluate	O
the	O
true	O
effect	O
of	O
tumor	B-DS
size	O
,	O
as	O
well	O
as	O
the	O
relative	O
importance	O
of	O
the	O
metastatic	O
lymph	O
nodes	O
in	O
various	O
stations	O
.	O

6	O
.	O

Surgical	O
Management	O
of	O
ICC	B-DS

Complete	O
surgical	O
resection	O
of	O
ICC	B-DS
with	O
negative	O
margins	O
(	O
R0	O
resection	O
)	O
currently	O
represents	O
the	O
only	O
potentially	O
curative	O
option	O
.	O

Because	O
a	O
subset	O
of	O
patients	O
with	O
ICC	B-DS
will	O
have	O
metastatic	B-DS
disease	I-DS
that	O
was	O
not	O
identified	O
on	O
preoperative	O
imaging	O
,	O
some	O
surgeons	O
advocate	O
for	O
a	O
staging	O
laparoscopy	O
prior	O
to	O
laparotomy	O
for	O
resection	O
.	O

While	O
data	O
are	O
lacking	O
with	O
respect	O
to	O
the	O
diagnostic	O
yield	O
of	O
staging	O
laparoscopy	O
,	O
there	O
have	O
been	O
reports	O
suggesting	O
a	O
potential	O
role	O
in	O
ICC	B-DS
.	O

In	O
a	O
study	O
of	O
39	O
patients	O
with	O
potentially	O
resectable	O
ICC	B-DS
,	O
staging	O
laparoscopy	O
identified	O
peritoneal	B-DS
carcinomatosis	I-DS
(	O
11	O
/	O
14	O
)	O
and	O
liver	B-DS
metastases	I-DS
(	O
5	O
/	O
14	O
)	O
in	O
a	O
small	O
subset	O
of	O
patients	O
,	O
thereby	O
avoiding	O
an	O
unnecessary	O
laparotomy	O
in	O
36	O
%	O
of	O
patients	O
[	O
52	O
].	O

In	O
a	O
second	O
series	O
of	O
22	O
patients	O
with	O
potentially	O
resectable	O
ICC	B-DS
,	O
staging	O
laparoscopy	O
detected	O
peritoneal	O
or	O
intrahepatic	O
metastases	O
in	O
6	O
(	O
27	O
%)	O
patients	O
[	O
53	O
].	O

Due	O
to	O
the	O
paucity	O
of	O
evidence	O
,	O
staging	O
laparoscopy	O
is	O
not	O
routinely	O
performed	O
for	O
patients	O
with	O
potentially	O
resectable	O
ICC	B-DS
.	O

Surgical	O
resection	O
should	O
be	O
offered	O
to	O
all	O
patients	O
who	O
are	O
appropriate	O
surgical	O
candidates	O
with	O
potentially	O
resectable	O
disease	O
.	O

Evaluation	O
of	O
SEER	O
data	O
from	O
1988	O
to	O
2003	O
found	O
,	O
however	O
,	O
that	O
only	O
37	O
%	O
of	O
patients	O
with	O
localized	B-DS
disease	I-DS
underwent	O
cancer	B-DS
directed	O
surgery	O
[	O
54	O
].	O

While	O
the	O
reasons	O
for	O
which	O
patients	O
did	O
not	O
undergo	O
surgery	O
were	O
not	O
evaluated	O
in	O
the	O
study	O
,	O
the	O
reasons	O
are	O
likely	O
multifactorial	O
.	O

ICC	B-DS
often	O
presents	O
as	O
a	O
large	O
,	O
locally	O
advanced	O
tumor	B-DS
that	O
can	O
make	O
surgery	O
technically	O
challenging	O
,	O
often	O
requiring	O
extensive	O
resection	O
to	O
achieve	O
negative	O
margins	O
.	O

Sortiropoulos	O
et	O
al	O
.	O
examined	O
41	O
R0	O
ICC	B-DS
resections	O
from	O
1998	O
to	O
2006	O
and	O
found	O
that	O
78	O
%	O
required	O
extended	O
hepatectomy	O
and	O
29	O
%	O
required	O
resection	O
of	O
the	O
hilar	O
bifurcation	O
[	O
55	O
].	O

In	O
addition	O
,	O
partial	O
resection	O
of	O
the	O
diaphragm	O
,	O
bile	O
duct	O
reconstruction	O
,	O
and	O
vascular	O
reconstruction	O
were	O
also	O
noted	O
.	O

A	O
second	O
study	O
from	O
Memorial	O
Sloan	O
Kettering	O
Cancer	O
Center	O
noted	O
that	O
only	O
30	O
%	O
of	O
patients	O
diagnosed	O
with	O
ICC	B-DS
were	O
surgical	O
candidates	O
(	O
n	O
=	O
82	O
).	O

Among	O
the	O
82	O
patients	O
who	O
underwent	O
surgical	O
resection	O
for	O
ICC	B-DS
during	O
the	O
16	O
-	O
year	O
study	O
period	O
,	O
78	O
%	O
required	O
major	O
hepatectomy	O
with	O
49	O
%	O
requiring	O
an	O
extended	O
hepatectomy	O
,	O
20	O
.	O
7	O
%	O
requiring	O
extrahepatic	O
bile	O
duct	O
resection	O
,	O
and	O
8	O
.	O
5	O
%	O
requiring	O
vascular	O
resection	O
[	O
56	O
].	O

These	O
studies	O
reiterate	O
how	O
extensive	O
resections	O
are	O
often	O
required	O
to	O
obtain	O
R0	O
margins	O
for	O
of	O
ICC	B-DS
.	O

The	O
use	O
of	O
routine	O
lymphadenectomy	O
is	O
not	O
well	O
defined	O
in	O
ICC	B-DS
resection	O
.	O

While	O
lymphadenectomy	O
is	O
often	O
standard	O
in	O
many	O
Eastern	O
centers	O
,	O
it	O
is	O
not	O
universally	O
performed	O
in	O
many	O
Western	O
countries	O
[	O
57	O
].	O

In	O
the	O
2009	O
evaluation	O
of	O
SEER	O
data	O
by	O
Nathan	O
et	O
al	O
.,	O
the	O
authors	O
noted	O
that	O
only	O
one	O
-	O
half	O
of	O
the	O
patients	O
who	O
underwent	O
resection	O
for	O
ICC	B-DS
had	O
at	O
least	O
one	O
lymph	O
node	O
examined	O
,	O
and	O
,	O
of	O
these	O
,	O
32	O
%	O
were	O
found	O
to	O
have	O
metastatic	B-DS
nodal	I-DS
disease	I-DS
[	O
50	O
].	O

A	O
second	O
meta	O
-	O
analysis	O
from	O
the	O
same	O
group	O
analyzed	O
4756	O
patients	O
undergoing	O
curative	O
-	O
intent	O
surgical	O
treatment	O
and	O
demonstrated	O
that	O
34	O
%	O
of	O
patients	O
who	O
underwent	O
lymphadenectomy	O
had	O
lymph	B-DS
node	I-DS
metastasis	I-DS
[	O
58	O
].	O

Some	O
investigators	O
,	O
however	O
,	O
argue	O
that	O
the	O
procedure	O
is	O
unnecessary	O
.	O

A	O
retrospective	O
study	O
from	O
Japan	O
which	O
evaluated	O
68	O
patients	O
with	O
mass	O
-	O
forming	O
ICC	B-DS
recommended	O
against	O
routine	O
lymphadenectomy	O
as	O
the	O
authors	O
argued	O
that	O
there	O
was	O
survival	O
benefit	O
associated	O
with	O
lymphadenectomy	O
.	O

A	O
different	O
retrospective	O
study	O
from	O
China	O
of	O
124	O
patients	O
with	O
ICC	B-DS
who	O
underwent	O
surgical	O
resection	O
from	O
2006	O
to	O
2007	O
similarly	O
showed	O
no	O
survival	O
benefit	O
among	O
patients	O
who	O
underwent	O
lymphadenectomy	O
and	O
had	O
nodal	O
metastasis	O
[	O
59	O
].	O

Lymphadenectomy	O
may	O
,	O
however	O
,	O
be	O
important	O
to	O
accurate	O
stage	O
patients	O
.	O

Multiple	O
studies	O
have	O
noted	O
that	O
overall	O
nodal	O
status	O
(	O
N0	O
versus	O
N1	O
),	O
as	O
well	O
as	O
the	O
number	O
of	O
nodal	O
metastases	O
,	O
strongly	O
predicts	O
prognosis	O
[	O
57	O
,	O
60	O
].	O

In	O
a	O
study	O
using	O
an	O
international	O
multi	O
-	O
institutional	O
database	O
evaluating	O
449	O
patients	O
between	O
1973	O
and	O
2010	O
,	O
248	O
(	O
55	O
%)	O
underwent	O
lymphadenectomy	O
and	O
74	O
(	O
30	O
%)	O
were	O
found	O
to	O
have	O
lymph	B-DS
node	I-DS
metastasis	I-DS
[	O
60	O
].	O

N1	O
disease	O
had	O
an	O
adverse	O
effect	O
on	O
overall	O
survival	O
(	O
median	O
survival	O
:	O
N0	O
:	O
30	O
months	O
versus	O
N1	O
:	O
24	O
months	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
[	O
60	O
].	O

A	O
recent	O
retrospective	O
study	O
of	O
221	O
patients	O
from	O
Japan	O
similarly	O
reported	O
that	O
lymph	B-DS
node	I-DS
metastasis	I-DS
was	O
a	O
strong	O
,	O
independent	O
prognostic	O
factor	O
of	O
survival	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
HR	O
:	O
2	O
.	O
577	O
,	O
and	O
95	O
%	O
CI	O
:	O
1	O
.	O
742	O
–	O
3	O
.	O
813	O
)	O
[	O
61	O
].	O

Given	O
the	O
relative	O
high	O
incidence	O
of	O
patients	O
found	O
to	O
have	O
lymph	B-DS
node	I-DS
metastasis	I-DS
(	O
30	O
%)	O
and	O
the	O
prognostic	O
implications	O
,	O
lymphadenectomy	O
should	O
be	O
strongly	O
considered	O
in	O
patients	O
undergoing	O
surgical	O
resection	O
for	O
ICC	B-DS
.	O

7	O
.	O

Outcomes	O
following	O
Surgery	O

Five	O
-	O
year	O
overall	O
survival	O
following	O
resection	O
for	O
ICC	B-DS
ranges	O
from	O
14	O
%	O
to	O
40	O
%	O
when	O
examining	O
data	O
published	O
from	O
1977	O
to	O
2007	O
[	O
5	O
,	O
38	O
,	O
50	O
,	O
56	O
,	O
62	O
–	O
74	O
].	O

There	O
does	O
seem	O
to	O
be	O
an	O
improvement	O
in	O
overall	O
5	O
-	O
year	O
survival	O
documented	O
in	O
the	O
past	O
decade	O
,	O
resulting	O
in	O
a	O
cumulative	O
34	O
.	O
4	O
%	O
improvement	O
in	O
survival	O
from	O
1992	O
to	O
2002	O
[	O
38	O
,	O
62	O
].	O

Data	O
from	O
one	O
high	O
volume	O
center	O
reported	O
an	O
overall	O
5	O
-	O
year	O
survival	O
of	O
40	O
%	O
with	O
an	O
increase	O
in	O
5	O
-	O
year	O
survival	O
,	O
as	O
well	O
as	O
the	O
incidence	O
of	O
R0	O
resection	O
,	O
when	O
comparing	O
patients	O
who	O
underwent	O
resection	O
from	O
1973	O
to	O
1995	O
versus	O
those	O
patients	O
who	O
underwent	O
resection	O
from	O
1996	O
to	O
2004	O
[	O
72	O
].	O

A	O
major	O
concern	O
following	O
surgery	O
for	O
ICC	B-DS
is	O
disease	O
recurrence	O
.	O

In	O
2009	O
,	O
Choi	O
et	O
al	O
.	O
reported	O
a	O
5	O
-	O
year	O
survival	O
of	O
39	O
.	O
5	O
%,	O
but	O
the	O
median	O
disease	O
-	O
free	O
survival	O
time	O
was	O
only	O
12	O
.	O
3	O
months	O
[	O
67	O
].	O

The	O
overall	O
risk	O
of	O
recurrence	O
following	O
resection	O
was	O
64	O
%	O
with	O
the	O
most	O
common	O
sites	O
of	O
recurrence	O
being	O
the	O
liver	O
(	O
56	O
%)	O
and	O
portal	O
lymph	O
nodes	O
(	O
31	O
%)	O
[	O
67	O
].	O

A	O
different	O
study	O
by	O
Endo	O
et	O
al	O
.	O
reported	O
a	O
disease	O
-	O
free	O
survival	O
of	O
26	O
months	O
,	O
with	O
more	O
than	O
50	O
%	O
of	O
the	O
patients	O
developing	O
recurrence	O
following	O
resection	O
;	O
the	O
liver	O
again	O
was	O
the	O
most	O
common	O
site	O
of	O
recurrence	O
(	O
63	O
%)	O
[	O
56	O
].	O

Upon	O
further	O
analysis	O
,	O
the	O
incidence	O
of	O
recurrence	O
in	O
patients	O
with	O
solitary	B-DS
tumors	I-DS
without	O
lymph	B-DS
node	I-DS
metastases	I-DS
was	O
only	O
47	O
%,	O
while	O
recurrence	O
among	O
patients	O
with	O
multiple	B-DS
tumors	I-DS
and	O
lymph	B-DS
node	I-DS
metastasis	I-DS
was	O
93	O
%	O
[	O
56	O
].	O

A	O
larger	O
study	O
of	O
301	O
patients	O
who	O
underwent	O
resection	O
for	O
ICC	B-DS
from	O
1990	O
to	O
2011	O
found	O
a	O
53	O
.	O
5	O
%	O
recurrence	O
rate	O
with	O
the	O
most	O
common	O
site	O
of	O
recurrence	O
being	O
intrahepatic	O
[	O
75	O
].	O

Macrovascular	O
invasion	O
,	O
lymph	B-DS
node	I-DS
metastasis	I-DS
,	O
and	O
tumor	B-DS
size	O
>	O
5	O
cm	O
were	O
all	O
independently	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Recently	O
,	O
a	O
collaboration	O
between	O
13	O
major	O
hepatobiliary	O
centers	O
in	O
the	O
US	O
,	O
Europe	O
,	O
and	O
Asia	O
compiled	O
data	O
from	O
514	O
patients	O
who	O
underwent	O
surgical	O
resection	O
for	O
ICC	B-DS
from	O
1990	O
to	O
2011	O
[	O
76	O
].	O

From	O
these	O
data	O
,	O
a	O
nomogram	O
to	O
predict	O
long	O
-	O
term	O
survival	O
after	O
resection	O
was	O
created	O
using	O
a	O
point	O
system	O
for	O
each	O
of	O
the	O
6	O
variables	O
found	O
to	O
be	O
significant	O
including	O
age	O
,	O
tumor	B-DS
size	O
,	O
number	O
of	O
tumors	B-DS
,	O
nodal	O
status	O
,	O
vascular	O
invasion	O
,	O
and	O
cirrhosis	B-DS
.	O

Each	O
of	O
these	O
variables	O
was	O
assigned	O
a	O
weighted	O
point	O
score	O
and	O
the	O
higher	O
total	O
score	O
was	O
correlated	O
with	O
a	O
worse	O
prognosis	O
[	O
76	O
].	O

Patients	O
in	O
the	O
lowest	O
quartile	O
had	O
a	O
median	O
survival	O
time	O
of	O
14	O
.	O
8	O
months	O
compared	O
with	O
80	O
.	O
2	O
months	O
for	O
the	O
patients	O
in	O
the	O
highest	O
quartile	O
[	O
76	O
].	O

The	O
high	O
recurrence	O
rate	O
and	O
general	O
poor	O
long	O
-	O
term	O
prognosis	O
associated	O
with	O
resected	O
ICC	B-DS
reinforce	O
the	O
need	O
for	O
more	O
effective	O
adjuvant	O
therapies	O
.	O

8	O
.	O

Nonsurgical	O
Management	O
of	O
ICC	B-DS

8	O
.	O
1	O
.	O

Systemic	O
Therapy	O

A	O
significant	O
proportion	O
of	O
patients	O
diagnosed	O
with	O
ICC	B-DS
are	O
unresectable	O
at	O
the	O
time	O
of	O
diagnosis	O
resulting	O
in	O
a	O
median	O
survival	O
time	O
of	O
5	O
to	O
8	O
months	O
[	O
5	O
,	O
77	O
].	O

Randomized	O
,	O
phase	O
three	O
clinical	O
trials	O
examining	O
chemotherapy	O
have	O
been	O
difficult	O
to	O
conduct	O
for	O
ICC	B-DS
likely	O
due	O
to	O
the	O
small	O
number	O
of	O
patients	O
and	O
the	O
heterogeneous	O
nature	O
of	O
biliary	O
tract	O
malignancies	O
.	O

Historically	O
,	O
5	O
-	O
FU	O
was	O
the	O
first	O
chemotherapeutic	O
agent	O
used	O
in	O
unresectable	O
ICC	B-DS
with	O
only	O
a	O
10	O
%	O
response	O
rate	O
as	O
a	O
single	O
agent	O
[	O
78	O
].	O

In	O
a	O
small	O
study	O
of	O
90	O
patients	O
which	O
included	O
pancreatic	O
(	O
53	O
patients	O
)	O
as	O
well	O
as	O
biliary	B-DS
tract	I-DS
cancers	I-DS
(	O
37	O
patients	O
),	O
5	O
-	O
FU	O
,	O
leucovorin	O
,	O
and	O
etoposide	O
therapy	O
showed	O
a	O
significantly	O
longer	O
overall	O
survival	O
time	O
versus	O
best	O
supportive	O
care	O
(	O
median	O
6	O
versus	O
2	O
.	O
5	O
months	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
[	O
79	O
].	O

Chemotherapy	O
for	O
ICC	B-DS
has	O
evolved	O
over	O
time	O
due	O
to	O
multiple	O
small	O
phase	O
2	O
studies	O
showing	O
improved	O
response	O
rates	O
of	O
22	O
%–	O
50	O
%	O
with	O
gemcitabine	O
based	O
combination	O
therapies	O
compared	O
to	O
the	O
traditional	O
response	O
rates	O
of	O
10	O
%–	O
30	O
%	O
with	O
fluoropyrimidine	O
based	O
chemotherapy	O
regimens	O
[	O
78	O
,	O
80	O
–	O
84	O
].	O

To	O
date	O
,	O
there	O
have	O
not	O
yet	O
been	O
any	O
trials	O
that	O
separate	O
ICC	B-DS
and	O
ECC	O
.	O

In	O
2010	O
,	O
the	O
Advanced	O
Biliary	B-DS
Cancer	I-DS
-	O
(	O
ABC	O
-)	O
02	O
trial	O
was	O
published	O
.	O

This	O
was	O
the	O
first	O
phase	O
III	O
,	O
randomized	O
control	O
trial	O
in	O
patients	O
with	O
advanced	O
biliary	B-DS
tract	I-DS
cancer	I-DS
that	O
compared	O
single	O
agent	O
gemcitabine	O
with	O
combination	O
of	O
gemcitabine	O
and	O
cisplatin	O
[	O
85	O
].	O

The	O
study	O
was	O
comprised	O
of	O
410	O
patients	O
with	O
metastatic	O
(	O
75	O
%)	O
or	O
locally	O
advanced	O
(	O
25	O
%)	O
biliary	B-DS
tract	I-DS
cancers	I-DS
.	O

Data	O
from	O
the	O
trial	O
demonstrated	O
that	O
the	O
combination	O
of	O
gemcitabine	O
and	O
cisplatin	O
offered	O
a	O
significant	O
progression	O
-	O
free	O
(	O
median	O
of	O
8	O
.	O
4	O
versus	O
6	O
.	O
5	O
months	O
;	O
hazard	O
ratio	O
(	O
HR	O
):	O
0	O
.	O
72	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
0	O
.	O
57	O
–	O
0	O
.	O
90	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
as	O
well	O
as	O
overall	O
survival	O
(	O
median	O
of	O
11	O
.	O
7	O
versus	O
8	O
.	O
3	O
months	O
;	O
HR	O
:	O
0	O
.	O
70	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
54	O
–	O
0	O
.	O
89	O
;	O
P	O
=	O
0	O
.	O
002	O
)	O
compared	O
with	O
gemcitabine	O
alone	O
at	O
a	O
median	O
follow	O
-	O
up	O
of	O
8	O
.	O
2	O
months	O
.	O

While	O
this	O
study	O
did	O
not	O
stratify	O
bile	B-DS
duct	I-DS
cancers	I-DS
by	O
location	O
,	O
upon	O
subgroup	O
analysis	O
,	O
the	O
survival	O
benefit	O
persisted	O
when	O
patients	O
with	O
cholangiocarcinoma	B-DS
(	O
59	O
%,	O
241	O
patients	O
)	O
were	O
evaluated	O
(	O
HR	O
:	O
0	O
.	O
54	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
34	O
–	O
0	O
.	O
94	O
)	O
[	O
85	O
].	O

This	O
“	O
doublet	O
”	O
regimen	O
is	O
now	O
considered	O
standard	O
of	O
care	O
due	O
to	O
the	O
survival	O
advantage	O
noted	O
in	O
this	O
trial	O
,	O
as	O
well	O
as	O
its	O
relatively	O
favorable	O
safety	O
profile	O
.	O

The	O
ABC	O
-	O
02	O
trial	O
also	O
demonstrated	O
the	O
possibility	O
of	O
performing	O
quality	O
phase	O
III	O
trials	O
in	O
rare	B-DS
diseases	I-DS
such	O
as	O
cholangiocarcinoma	B-DS
.	O

The	O
use	O
of	O
chemotherapy	O
for	O
ICC	B-DS
in	O
the	O
adjuvant	O
postsurgical	O
setting	O
is	O
even	O
less	O
well	O
studied	O
.	O

A	O
small	O
study	O
from	O
China	O
looked	O
at	O
40	O
patients	O
receiving	O
adjuvant	O
gemcitabine	O
after	O
resection	O
for	O
biliary	B-DS
tract	I-DS
cancer	I-DS
and	O
showed	O
an	O
overall	O
increase	O
in	O
survival	O
on	O
subgroup	O
analysis	O
for	O
ICC	B-DS
patients	O
(	O
HR	O
:	O
0	O
.	O
09	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
01	O
–	O
0	O
.	O
67	O
)	O
[	O
86	O
].	O

This	O
study	O
,	O
however	O
,	O
was	O
very	O
small	O
and	O
the	O
results	O
are	O
somewhat	O
difficult	O
to	O
interpret	O
in	O
isolation	O
.	O

Given	O
the	O
poor	O
results	O
achieved	O
with	O
cytotoxic	O
chemotherapy	O
,	O
there	O
has	O
been	O
interest	O
in	O
understanding	O
potential	O
targetable	O
molecular	O
mechanisms	O
and	O
mutations	O
critical	O
for	O
oncogenesis	O
in	O
cholangiocarcinoma	B-DS
.	O

Targets	O
of	O
the	O
vascular	B-GP
endothelial	I-GP
growth	I-GP
factor	I-GP
(	O
VEGF	B-GP
)	O
pathway	O
,	O
involved	O
in	O
angiogenesis	O
,	O
and	O
epidermal	B-GP
growth	I-GP
factor	I-GP
(	O
EGF	B-GP
)	O
pathway	O
,	O
involved	O
in	O
cell	O
proliferation	O
,	O
have	O
been	O
studied	O
in	O
several	O
phase	O
II	O
trials	O
.	O

Agents	O
such	O
as	O
sorafenib	O
[	O
87	O
,	O
88	O
],	O
erlotinib	O
[	O
89	O
–	O
91	O
],	O
lapatinib	O
[	O
92	O
],	O
panitumumab	O
[	O
93	O
],	O
cetuximab	O
[	O
94	O
],	O
sunitinib	O
[	O
95	O
],	O
and	O
bevacizumab	O
[	O
89	O
,	O
96	O
]	O
have	O
all	O
been	O
evaluated	O
in	O
phase	O
II	O
trials	O
as	O
single	O
agents	O
or	O
in	O
combination	O
with	O
gemcitabine	O
combination	O
with	O
no	O
significant	O
increase	O
in	O
overall	O
survival	O
noted	O
.	O

Ongoing	O
study	O
of	O
these	O
pathways	O
as	O
well	O
as	O
others	O
found	O
to	O
be	O
implicated	O
in	O
cholangiocarcinoma	B-DS
including	O
map	B-GP
kinase	I-GP
pathway	O
,	O
hepatocyte	B-GP
growth	I-GP
factor	I-GP
,	O
BRAF	B-GP
,	O
and	O
platelet	B-GP
derived	I-GP
growth	I-GP
factor	I-GP
hopefully	O
will	O
lead	O
to	O
effective	O
targeted	O
therapy	O
(	O
Figure	O
3	O
)	O
[	O
97	O
].	O

8	O
.	O
2	O
.	O

Radiation	O

The	O
role	O
of	O
external	O
beam	O
radiation	O
therapy	O
in	O
the	O
adjuvant	O
setting	O
as	O
well	O
as	O
in	O
inoperable	O
ICC	B-DS
treatment	O
is	O
controversial	O
.	O

In	O
the	O
adjuvant	O
setting	O
,	O
most	O
studies	O
do	O
not	O
break	O
down	O
patients	O
by	O
location	O
of	O
cholangiocarcinoma	B-DS
.	O

In	O
a	O
retrospective	O
study	O
by	O
Shinohara	O
et	O
al	O
.,	O
3	O
,	O
839	O
patients	O
with	O
ICC	B-DS
in	O
the	O
SEER	O
database	O
were	O
analyzed	O
.	O

7	O
%	O
of	O
the	O
patients	O
analyzed	O
underwent	O
surgical	O
resection	O
and	O
also	O
received	O
adjuvant	O
radiation	O
therapy	O
.	O

The	O
median	O
overall	O
survival	O
was	O
higher	O
among	O
patients	O
who	O
underwent	O
surgery	O
plus	O
adjuvant	O
radiation	O
therapy	O
versus	O
surgery	O
alone	O
(	O
11	O
versus	O
6	O
months	O
;	O
P	O
=	O
0	O
.	O
014	O
)	O
[	O
98	O
].	O

While	O
this	O
study	O
suggested	O
the	O
possible	O
benefit	O
of	O
radiation	O
in	O
patients	O
with	O
R1	O
resections	O
,	O
it	O
was	O
retrospective	O
,	O
and	O
future	O
prospective	O
trials	O
are	O
needed	O
to	O
validate	O
the	O
benefit	O
of	O
radiation	O
therapy	O
as	O
a	O
local	O
treatment	O
in	O
the	O
adjuvant	O
setting	O
.	O

The	O
utilization	O
of	O
radiation	O
for	O
ICC	B-DS
has	O
been	O
examined	O
more	O
in	O
the	O
unresectable	O
setting	O
.	O

Zeng	O
et	O
al	O
.	O
published	O
a	O
small	O
case	O
-	O
control	O
study	O
of	O
external	O
beam	O
radiotherapy	O
for	O
ICC	B-DS
in	O
which	O
22	O
unresectable	O
patients	O
received	O
a	O
median	O
total	O
of	O
50	O
Gy	O
of	O
radiation	O
therapy	O
given	O
in	O
2	O
Gy	O
/	O
fraction	O
daily	O
doses	O
[	O
99	O
].	O

The	O
1	O
-	O
and	O
2	O
-	O
year	O
overall	O
survival	O
among	O
patients	O
with	O
unresectable	O
ICC	B-DS
who	O
underwent	O
radiotherapy	O
versus	O
those	O
patients	O
who	O
did	O
not	O
was	O
36	O
.	O
1	O
%	O
versus	O
19	O
%	O
and	O
5	O
.	O
2	O
%	O
versus	O
4	O
.	O
7	O
%,	O
respectively	O
;	O
in	O
addition	O
,	O
the	O
objective	O
response	O
rate	O
was	O
36	O
.	O
4	O
%.	O

In	O
a	O
separate	O
phase	O
II	O
study	O
from	O
University	O
of	O
Michigan	O
,	O
46	O
patients	O
with	O
unresectable	O
ICC	B-DS
were	O
treated	O
and	O
evaluated	O
[	O
100	O
].	O

Of	O
note	O
,	O
patients	O
with	O
ICC	B-DS
who	O
underwent	O
hyperfactionated	O
radiation	O
therapy	O
with	O
concurrent	O
hepatic	O
arterial	O
fluorodeoxyuridine	O
with	O
a	O
median	O
dose	O
of	O
60	O
.	O
75	O
Gy	O
had	O
a	O
significantly	O
improved	O
overall	O
survival	O
compared	O
with	O
historical	O
controls	O
(	O
13	O
.	O
3	O
months	O
;	O
P	O
<	O
0	O
.	O
008	O
)	O
[	O
100	O
].	O

The	O
authors	O
reported	O
that	O
tumor	B-DS
dose	O
was	O
strongly	O
associated	O
with	O
survival	O
,	O
as	O
patients	O
who	O
received	O
doses	O
greater	O
than	O
or	O
equal	O
to	O
75	O
Gy	O
had	O
a	O
better	O
median	O
survival	O
(	O
23	O
.	O
9	O
months	O
)	O
compared	O
with	O
patients	O
who	O
received	O
a	O
lower	O
dose	O
(	O
14	O
.	O
9	O
months	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
[	O
100	O
].	O

In	O
yet	O
another	O
study	O
by	O
the	O
Mayo	O
Clinic	O
,	O
the	O
authors	O
reported	O
on	O
10	O
patients	O
with	O
unresectable	O
or	O
recurrent	O
ICC	B-DS
treated	O
with	O
abdominal	O
stereotactic	O
body	O
radiotherapy	O
(	O
SBRT	O
)	O
[	O
101	O
].	O

Patients	O
were	O
treated	O
with	O
a	O
median	O
of	O
55	O
Gy	O
and	O
had	O
a	O
median	O
follow	O
-	O
up	O
of	O
14	O
months	O
.	O

Local	O
control	O
,	O
defined	O
as	O
freedom	O
from	O
progression	O
in	O
the	O
SBRT	O
field	O
,	O
was	O
100	O
%;	O
however	O
,	O
4	O
patients	O
experienced	O
progression	O
at	O
other	O
sites	O
.	O

Overall	O
survival	O
estimates	O
at	O
6	O
and	O
12	O
months	O
were	O
83	O
%	O
and	O
73	O
%,	O
respectively	O
[	O
101	O
].	O

Yttrium	O
-	O
90	O
radioembolization	O
both	O
alone	O
and	O
in	O
combination	O
with	O
chemotherapy	O
has	O
been	O
studied	O
as	O
an	O
alternative	O
treatment	O
option	O
in	O
patients	O
with	O
unresectable	O
ICC	B-DS
.	O

A	O
pooled	O
analysis	O
of	O
11	O
previously	O
published	O
studies	O
showed	O
an	O
overall	O
weighted	O
median	O
survival	O
of	O
15	O
.	O
5	O
months	O
(	O
range	O
7	O
–	O
22	O
.	O
2	O
)	O
from	O
the	O
initiation	O
of	O
treatment	O
[	O
102	O
].	O

While	O
none	O
of	O
these	O
were	O
randomized	O
trials	O
,	O
the	O
outcomes	O
compare	O
well	O
with	O
published	O
overall	O
survival	O
after	O
treatment	O
with	O
systemic	O
cisplatin	O
-	O
gemcitabine	O
(	O
11	O
.	O
7	O
months	O
)	O
[	O
85	O
]	O
and	O
TACE	O
(	O
13	O
.	O
8	O
months	O
)	O
[	O
103	O
].	O

These	O
studies	O
provide	O
promising	O
evidence	O
of	O
success	O
of	O
radiation	O
therapy	O
as	O
a	O
local	O
,	O
noninvasive	O
treatment	O
option	O
in	O
ICC	B-DS
;	O
however	O
,	O
further	O
validation	O
is	O
needed	O
in	O
an	O
upcoming	O
prospective	O
multicenter	O
trial	O
.	O

8	O
.	O
3	O
.	O

Intra	O
-	O
Arterial	O
Therapy	O

Another	O
local	O
treatment	O
option	O
for	O
unresectable	O
ICC	B-DS
is	O
intra	O
-	O
arterial	O
therapy	O
,	O
which	O
most	O
commonly	O
involves	O
transarterial	O
chemoembolization	O
(	O
TACE	O
).	O

TACE	O
was	O
first	O
described	O
in	O
the	O
early	O
1980s	O
in	O
the	O
treatment	O
of	O
HCC	B-DS
[	O
104	O
–	O
106	O
]	O
and	O
has	O
more	O
recently	O
been	O
demonstrated	O
to	O
provide	O
survival	O
benefit	O
for	O
patients	O
with	O
HCC	B-DS
compared	O
with	O
best	O
supportive	O
care	O
[	O
107	O
,	O
108	O
].	O

Data	O
on	O
intra	O
-	O
arterial	O
therapy	O
for	O
ICC	B-DS
are	O
limited	O
.	O

A	O
2005	O
study	O
of	O
17	O
patients	O
with	O
unresectable	O
ICC	B-DS
at	O
Johns	O
Hopkins	O
Hospital	O
from	O
1995	O
to	O
2004	O
found	O
that	O
the	O
treatment	O
was	O
well	O
tolerated	O
by	O
82	O
%	O
of	O
the	O
patients	O
[	O
109	O
].	O

Imaging	O
was	O
performed	O
4	O
–	O
6	O
weeks	O
following	O
each	O
TACE	O
treatment	O
to	O
determine	O
clinical	O
response	O
and	O
the	O
need	O
for	O
additional	O
treatments	O
.	O

The	O
median	O
overall	O
survival	O
in	O
this	O
study	O
was	O
23	O
months	O
and	O
two	O
patients	O
were	O
converted	O
to	O
resectable	O
disease	O
and	O
ultimately	O
underwent	O
an	O
R0	O
resection	O
[	O
109	O
].	O

A	O
2008	O
University	O
of	O
Pittsburg	O
study	O
examined	O
the	O
use	O
of	O
TACE	O
in	O
48	O
patients	O
(	O
37	O
with	O
central	O
cholangiocarcinoma	B-DS
and	O
5	O
with	O
peripheral	O
tumors	B-DS
)	O
with	O
unresectable	O
cholangiocarcinoma	B-DS
.	O

This	O
study	O
found	O
that	O
TACE	O
with	O
a	O
median	O
of	O
3	O
.	O
5	O
treatments	O
using	O
a	O
gemcitabine	O
-	O
cisplatin	O
combination	O
resulted	O
in	O
an	O
increased	O
overall	O
survival	O
compared	O
with	O
gemcitabine	O
alone	O
TACE	O
treatment	O
(	O
13	O
.	O
8	O
versus	O
6	O
.	O
3	O
months	O
)	O
[	O
110	O
].	O

A	O
separate	O
2013	O
retrospective	O
study	O
investigated	O
198	O
patients	O
with	O
advanced	O
ICC	B-DS
from	O
five	O
major	O
hepatobiliary	O
centers	O
in	O
the	O
US	O
who	O
were	O
treated	O
with	O
intra	O
-	O
arterial	O
therapy	O
between	O
1992	O
and	O
2012	O
[	O
103	O
].	O

A	O
majority	O
of	O
the	O
patients	O
underwent	O
TACE	O
and	O
,	O
on	O
assessment	O
of	O
tumor	B-DS
response	O
,	O
25	O
.	O
5	O
%	O
of	O
the	O
patients	O
were	O
noted	O
to	O
have	O
a	O
complete	O
or	O
partial	O
response	O
[	O
103	O
].	O

When	O
evaluated	O
with	O
modified	O
response	O
evaluation	O
criteria	O
in	O
solid	B-DS
tumors	I-DS
(	O
mRECIST	O
),	O
intra	O
-	O
arterial	O
therapy	O
was	O
independently	O
associated	O
with	O
improved	O
survival	O
[	O
103	O
].	O

These	O
studies	O
suggest	O
that	O
intra	O
-	O
arterial	O
therapies	O
,	O
such	O
as	O
TACE	O
,	O
may	O
provide	O
a	O
therapeutic	O
benefit	O
to	O
some	O
patients	O
and	O
should	O
be	O
considered	O
when	O
treating	O
patients	O
with	O
advanced	O
disease	O
.	O

8	O
.	O
4	O
.	O

Ablation	O

For	O
patients	O
with	O
small	O
lesions	O
,	O
who	O
are	O
otherwise	O
unable	O
to	O
undergo	O
resection	O
,	O
radiofrequency	O
(	O
RFA	O
)	O
or	O
microwave	O
ablation	O
is	O
another	O
treatment	O
option	O
.	O

While	O
ablation	O
is	O
a	O
standard	O
treatment	O
for	O
HCC	B-DS
,	O
there	O
have	O
only	O
been	O
few	O
small	O
studies	O
regarding	O
its	O
efficacy	O
in	O
ICC	B-DS
[	O
3	O
,	O
111	O
–	O
117	O
].	O

Ablation	O
may	O
be	O
effective	O
in	O
providing	O
local	O
control	O
of	O
small	O
(<	O
3	O
–	O
5	O
cm	O
)	O
lesions	O
;	O
however	O
the	O
data	O
are	O
scarce	O
.	O

In	O
the	O
few	O
reported	O
studies	O
to	O
date	O
,	O
most	O
with	O
patient	O
sample	O
sizes	O
of	O
6	O
–	O
17	O
patients	O
,	O
primary	O
technical	O
effectiveness	O
measured	O
by	O
early	O
necrosis	O
was	O
seen	O
in	O
90	O
–	O
100	O
%	O
of	O
small	O
tumors	B-DS
(<	O
3	O
.	O
5	O
cm	O
).	O

One	O
-	O
and	O
3	O
-	O
year	O
survival	O
ranged	O
from	O
84	O
.	O
6	O
%	O
to	O
100	O
%	O
and	O
43	O
.	O
3	O
%	O
to	O
83	O
.	O
3	O
%,	O
respectively	O
.	O

Median	O
overall	O
survival	O
ranged	O
from	O
33	O
to	O
38	O
.	O
5	O
months	O
,	O
suggesting	O
that	O
ablation	O
may	O
have	O
a	O
survival	O
benefit	O
[	O
3	O
,	O
111	O
–	O
117	O
].	O

8	O
.	O
5	O
.	O

Liver	O
Transplantation	O

Liver	O
transplantation	O
as	O
a	O
treatment	O
for	O
ICC	B-DS
remains	O
controversial	O
.	O

The	O
role	O
of	O
transplantation	O
in	O
perihilar	B-DS
cholangiocarcinoma	I-DS
is	O
significantly	O
more	O
defined	O
;	O
for	O
perihilar	B-DS
cholangiocarcinoma	I-DS
,	O
there	O
are	O
strict	O
selection	O
criteria	O
,	O
including	O
the	O
requirement	O
of	O
neoadjuvant	O
chemotherapy	O
,	O
with	O
good	O
long	O
-	O
term	O
outcomes	O
such	O
as	O
a	O
recurrence	O
-	O
free	O
survival	O
at	O
5	O
years	O
of	O
65	O
%	O
[	O
118	O
].	O

The	O
data	O
on	O
transplantation	O
for	O
ICC	B-DS
,	O
however	O
,	O
are	O
not	O
as	O
defined	O
.	O

UCLA	O
reported	O
on	O
38	O
patients	O
who	O
underwent	O
liver	O
transplant	O
for	O
intrahepatic	O
or	O
hilar	B-DS
cholangiocarcinoma	I-DS
.	O

The	O
5	O
-	O
year	O
tumor	B-DS
recurrence	O
-	O
free	O
survival	O
was	O
higher	O
in	O
the	O
transplant	O
group	O
compared	O
with	O
those	O
who	O
underwent	O
hepatectomy	O
(	O
33	O
%	O
versus	O
0	O
%;	O
P	O
=	O
0	O
.	O
05	O
).	O

In	O
the	O
transplant	O
group	O
,	O
neoadjuvant	O
and	O
adjuvant	O
therapies	O
resulted	O
in	O
better	O
patient	O
survival	O
compared	O
with	O
no	O
therapy	O
or	O
adjuvant	O
therapy	O
only	O
(	O
47	O
%	O
versus	O
20	O
%	O
versus	O
33	O
%,	O
resp	O
.;	O
P	O
=	O
0	O
.	O
03	O
)	O
[	O
119	O
].	O

However	O
,	O
this	O
study	O
did	O
not	O
separate	O
out	O
intrahepatic	O
from	O
hilar	O
lesions	O
,	O
making	O
the	O
findings	O
difficult	O
to	O
interpret	O
.	O

A	O
retrospective	O
study	O
from	O
China	O
evaluated	O
20	O
patients	O
with	O
ICC	B-DS
who	O
underwent	O
liver	O
transplantation	O
and	O
reported	O
actuarial	O
survival	O
at	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
5	O
years	O
of	O
84	O
.	O
2	O
%,	O
43	O
.	O
7	O
%,	O
32	O
.	O
7	O
%,	O
and	O
21	O
.	O
8	O
%,	O
respectively	O
[	O
120	O
].	O

Tumor	B-DS
-	O
free	O
survival	O
at	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
5	O
years	O
was	O
55	O
.	O
6	O
%,	O
43	O
.	O
2	O
%,	O
28	O
.	O
8	O
%,	O
and	O
18	O
.	O
8	O
%,	O
respectively	O
.	O

On	O
multivariate	O
analysis	O
,	O
lymph	O
node	O
invasion	O
,	O
macrovascular	O
invasion	O
,	O
and	O
multiple	B-DS
tumors	I-DS
were	O
independent	O
predictors	O
of	O
survival	O
[	O
120	O
].	O

A	O
retrospective	O
multicenter	O
study	O
from	O
Spain	O
reported	O
on	O
29	O
patients	O
with	O
cirrhosis	B-DS
and	O
ICC	B-DS
<	O
2	O
cm	O
on	O
histologic	O
sectioning	O
after	O
liver	O
transplantation	O
[	O
121	O
].	O

Patients	O
with	O
small	O
tumors	B-DS
had	O
an	O
actuarial	O
survival	O
at	O
1	O
,	O
3	O
,	O
and	O
5	O
years	O
of	O
100	O
%,	O
73	O
%,	O
and	O
73	O
%,	O
respectively	O
[	O
121	O
].	O

There	O
were	O
no	O
recurrences	O
in	O
patients	O
with	O
tumors	B-DS
<	O
2	O
cm	O
compared	O
with	O
a	O
recurrence	O
of	O
36	O
.	O
4	O
%	O
among	O
patients	O
with	O
>	O
2	O
cm	O
ICC	B-DS
[	O
121	O
].	O

While	O
liver	O
transplantation	O
for	O
ICC	B-DS
may	O
have	O
a	O
future	O
role	O
,	O
the	O
overall	O
survival	O
outcomes	O
at	O
the	O
current	O
time	O
remain	O
generally	O
poor	O
.	O

As	O
such	O
,	O
transplantation	O
for	O
ICC	B-DS
should	O
probably	O
only	O
be	O
done	O
in	O
a	O
strict	O
protocol	O
-	O
based	O
setting	O
.	O

9	O
.	O

Summary	O

ICC	B-DS
is	O
the	O
second	O
most	O
common	O
primary	O
hepatic	O
malignancy	O
and	O
is	O
increasing	O
in	O
incidence	O
in	O
the	O
United	O
States	O
.	O

The	O
disease	O
remains	O
poorly	O
understood	O
;	O
however	O
patients	O
who	O
are	O
eligible	O
should	O
undergo	O
surgical	O
resection	O
,	O
as	O
an	O
R0	O
resection	O
remains	O
the	O
only	O
potentially	O
curative	O
treatment	O
.	O

Resection	O
often	O
requires	O
a	O
technically	O
complex	O
surgery	O
that	O
often	O
involves	O
an	O
extended	O
hepatic	O
resection	O
and	O
therefore	O
these	O
patients	O
are	O
probably	O
best	O
served	O
at	O
a	O
high	O
volume	O
center	O
.	O

Unfortunately	O
,	O
a	O
large	O
number	O
of	O
patients	O
with	O
ICC	B-DS
will	O
present	O
with	O
unresectable	O
disease	O
.	O

Therapeutic	O
options	O
for	O
patients	O
with	O
advanced	O
disease	O
include	O
systemic	O
and	O
locoregional	O
options	O
.	O

Ultimately	O
,	O
ICC	B-DS
remains	O
a	O
complex	O
clinical	O
challenge	O
that	O
demands	O
a	O
multidisciplinary	O
approach	O
.	O

Treatment	O
algorithm	O
for	O
intrahepatic	O
cholangiocarcinoma	O
.	O

MRI	O
and	O
pathologic	O
correlation	O
of	O
intrahepatic	O
cholangiocarcinoma	O
.	O

(	O
a	O
)	O
Yellow	O
-	O
grey	O
intrahepatic	O
mass	O
on	O
pathologic	O
specimen	O
.	O

(	O
b	O
)	O
Portal	O
venous	O
phase	O
MRI	O
of	O
intrahepatic	O
cholangiocarcinoma	O
designated	O
by	O
box	O
with	O
hypointense	O
lesion	O
.	O

(	O
c	O
)	O
Delayed	O
contrast	O
-	O
enhanced	O
MRI	O
of	O
the	O
same	O
lesion	O
showing	O
accumulation	O
of	O
contrast	O
within	O
the	O
lesion	O
.	O

Reprinted	O
from	O
Cancer	O
Imaging	O
[	O
42	O
].	O

Signaling	O
pathways	O
involved	O
in	O
intrahepatic	O
cholangiocarcinoma	O
and	O
the	O
corresponding	O
molecular	O
therapies	O
.	O

Reprinted	O
from	O
McMilan	O
Publishers	O
Ltd	O
.:	O
Oncogene	O
[	O
97	O
].	O

Risk	O
factors	O
for	O
cholangiocarcinoma	O
.	O

General	O
risk	O
factors	O

Inflammatory	O
risk	O
factors	O

Obesity	O

Primary	O
sclerosing	O
cholangitis	O

Tobacco	O
use	O

Hepatolithiasis	O

Age	O
>	O
65	O

Biliary	O
cirrhosis	O

Type	O
II	O
diabetes	O

Inflammatory	O
bowel	O
disease	O

Excessive	O
alcohol	O
intake	O

Biliary	O
-	O
enteric	O
anastomosis	O

NAFLD	O

Parasitic	O
risk	O
factors	O

Congenital	O
risk	O
factors	O

Clonorchis	O
sinensis	O

Caroli	O
'	O
s	O
disease	O

Opisthorchis	O
viverrini	O

Choledochal	O
cysts	O

Chemical	O
risk	O
factors	O

Congenital	O
hepatic	O
fibrosis	O

Nitrosamines	O

Bile	O
duct	O
adenomas	O

Vinyl	O
chloride	O

Biliary	O
papillomatosis	O

Thorotrast	O

Viral	O
risk	O
factors	O

Dioxin	O

Hepatitis	O
B	O

Oral	O
contraceptives	O

Hepatitis	O
C	O

Isoniazid	O

HIV	O

Asbestos	O


Radon	O

American	O
Joint	O
Committee	O
on	O
Cancer	O
(	O
AJCC	O
).	O

TNM	O
Staging	O
for	O
Intrahepatic	O
Bile	O
Duct	O
Tumors	O
(	O
7th	O
edition	O
,	O
2010	O
).	O

Primary	O
tumor	O
(	O
T	O
)	O




TX	O

Primary	O
tumor	O
cannot	O
be	O
assessed	O

T0	O

No	O
evidence	O
of	O
primary	O
tumor	O

Tis	O

Carcinoma	O
in	O
situ	O
(	O
intraductal	O
tumor	O
)	O

T1	O

Solitary	O
tumor	O
without	O
vascular	O
invasion	O

T2a	O

Solitary	O
tumor	O
with	O
vascular	O
invasion	O

T2b	O

Multiple	O
tumors	O
,	O
with	O
or	O
without	O
vascular	O
invasion	O

T3	O

Tumor	O
perforating	O
the	O
visceral	O
peritoneum	O
or	O
involving	O
the	O

Local	O
extra	O
hepatic	O
structures	O
by	O
direct	O
invasion	O
T4	O
Tumor	O
with	O
periductal	O
invasion	O

Regional	O
lymph	O
nodes	O
(	O
N	O
)	O




NX	O

Regional	O
lymph	O
nodes	O
cannot	O
be	O
assessed	O
N0	O
No	O
regional	O
lymph	O
node	O
metastasis	O

N1	O

Regional	O
lymph	O
node	O
metastasis	O
present	O

Distant	O
metastasis	O
(	O
M	O
)	O




M0	O

No	O
distant	O
metastasis	O

M1	O

Distant	O
metastasis	O
present	O

Anatomic	O
stage	O
groupings	O




Stage	O
0	O

Tis	O

N0	O

M0	O

Stage	O
I	O

T1	O

N0	O

M0	O

Stage	O
II	O

T2	O

N0	O

M0	O

Stage	O
III	O

T3	O

N0	O

M0	O

Stage	O
IVA	O

T4	O

N0	O

M0	O

Any	O
T	O

N1	O

M0	O

Stage	O
IVB	O

Any	O
T	O

Any	O
N	O

M1	O

